LLY
Eli Lilly and Company
LLY has the edge over YARW overall, supported by stronger fundamentals and lower modeled downside.
YARW
Yarrow Bioscience Inc
YARW trails on the overall score without a compensating advantage in the available component scores.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
YARW Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
YARW's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
YARW PE Valuation
YARW has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
YARW Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect YARW's losses to shrink, with revenue declining.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over YARW on earnings quality, reporting a profit while its opponent remains loss making.
YARW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$23.27 | +$21.23 |
| Q1 2026 | -$26.26 | +$22.74 |
| Q4 2025 | -$32.26 | +$14.24 |
| Q3 2023 | -$498.97 | -$111.97 |
| Q2 2023 | -$542.47 | +$69.53 |
| Q1 2023 | -$522.97 | +$305.03 |
| Q4 2022 | -$363.97 | +$914.03 |
| Q3 2022 | -$387.00 | +$216.00 |
YARW lost $23.27 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over YARW on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over YARW on profitability, with a higher operating margin.
YARW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $97K | +41% |
| Q1 2026 | $86K | -57% |
| Q4 2025 | $130K | +55% |
| Q3 2025 | $169K | +40% |
| Q2 2025 | $69K | -65% |
| Q1 2025 | $202K | +106% |
| Q4 2024 | $84K | +11% |
| Q3 2024 | $121K | +6.1% |
YARW's revenue is recovering but still below its 2020 peak: $97,000 last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3198% | +7733 points |
| Q1 2026 | -4437% | +116 points |
| Q4 2025 | -4015% | +11188 points |
| Q3 2025 | -4611% | +6208 points |
| Q2 2025 | -10930% | -5680 points |
| Q1 2025 | -4553% | +2978 points |
| Q4 2024 | -15202% | -6213 points |
| Q3 2024 | -10819% | -5351 points |
YARW's operating margin was −3198% last quarter, up 7732 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over YARW on cash generation, producing positive trailing cash flow while its opponent burns cash.
YARW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$8.8M |
| Q1 2026 | -$4.1M | +$7.4M |
| Q3 2025 | -$7.1M | +$1.4M |
| Q2 2025 | -$10.8M | -$2.3M |
| Q1 2025 | -$11.5M | -$3.5M |
| Q3 2024 | -$8.5M | -$3.4M |
| Q2 2024 | -$8.5M | +$1.1M |
| Q1 2024 | -$8M | -$2.5M |
YARW has burned cash in almost every quarter: −$17M over the past year, against −$39M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over YARW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
YARW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.6K shares |
| 1 year | +0.3% | +2.8K shares |
| 3 years | +1247% | +794K shares |
| 5 years | +1741% | +811K shares |
| Available history | +12794% | +851K shares |
YARW has 858,000 diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $15,000 |
| Q3 2025 | $7,000 |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
YARW Net Leverage
YARW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
YARW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 13.3 | Oversold |
YARW's weekly RSI is 40 (neutral) and its Stochastic is 13 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
YARW PE vs Healthcare Sector
YARW has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over YARW on trend strength, trading above more of its moving averages.
YARW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.0 | 2% below |
| 20 week MA | $28.4 | 31% below |
| 50 week MA | $29.3 | 33% below |
| 100 week MA | $47.7 | 59% below |
| 200 week MA | $102.9 | 81% below |
YARW is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over YARW on returns for 2026, with the stronger performance.
YARW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18,000.0 | $6,372.0 | -65% |
| 2021 | $6,372.0 | $1,008.0 | -84% |
| 2022 | $1,008.0 | $107.0 | -89% |
| 2023 | $107.0 | $116.5 | +8.9% |
| 2024 | $116.5 | $158.5 | +36% |
| 2025 | $158.5 | $29.4 | -81% |
| 2026 YTD | $29.4 | $19.6 | -33% |
YARW has finished lower in four of the last six years. It's down 33% so far in 2026.